Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus WILPO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus WILPO.
IMPOYZ vs WILPO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
Wilpo (setmelanotide) is a melanocortin 4 receptor (MC4R) agonist that activates the MC4R pathway to reduce appetite and increase energy expenditure.
100 mg orally twice daily
WILPO is not a known or approved drug. No standard dosing information available.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life of 12 hours (range 10-14 h). Steady-state achieved after 2-3 days. Requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Primarily renal (unchanged: 60%, glucuronide conjugate: 20%), biliary/fecal: 15%, other: 5%.
Category C
Category C
Unknown
Unknown